IMVT | Immunovant, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	25.64 - 26.46
52 Week Range	24.61 - 45.58
Beta	0.70
Implied Volatility	56.38%
IV Rank	62.17%
Day's Volume	317,925
Average Volume	840,943
Shares Outstanding	146,785,000
Market Cap	3,813,474,300
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-06-21

Valuation
Profitability
Growth
Health
P/E Ratio	-11.76
Forward P/E Ratio	N/A
EPS	-2.21
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	207
Country	USA
Website	IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT's peers: APLS, BGNE, IMAB, ABUS, ARQT, LEGN, PTGX, ISEE, AKRO, MDGL, ETNB, PLRX, ACLX, STOK, BPMC, AMLX, KRTX, DAWN, MRVI

*Chart delayed

Analyzing fundamentals for IMVT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see IMVT Fundamentals page.

Watching at IMVT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IMVT Technicals page.